Regeneron Pharmaceuticals (REGN) Reports Promising Phase 1/2 Tri

Regeneron (REGN) reported positive clinical data for ubamatamab in ovarian cancer and trevogrumab in obesity. Ubamatamab showed a 73% response rate in LGSOC patients, while trevogrumab preserved lean mass in obesity patients. Both drugs are in clinical trials, with REGN planning further studies. REGN stock is currently down 2.08%.

Regeneron Pharmaceuticals (REGN) reported positive initial data from a Phase 1/2 trial of ubamatamab for low-grade serous ovarian cancer, with a 73% response rate. The company plans further trials and FDA discussions. REGN is modestly undervalued with a GF Value of $907.43, a GF Score of 88, and a P/E ratio of 18.2x, matching its 5-year median.

Regeneron (REGN) shares fell 4% after expanding its alliance with Sanofi, with Sanofi paying $1B upfront and up to $7B in milestones for new antibodies. The deal leaves Dupixent profit-sharing terms unchanged, disappointing investors who expected better terms. Shares later recovered slightly to close down 2.9% at $736.56.

Regeneron Pharmaceuticals (REGN) reported Phase 1/2 trial data for ubamatamab, an ovarian cancer therapy. While all 19 patients experienced adverse events, 73% of heavily pretreated patients showed partial responses. Regeneron plans a Phase 3 trial and FDA data submission.

Regeneron Pharmaceuticals reported initial Phase 1/2 trial data for its ovarian cancer therapy, ubamatamab. The company's stock initially rose but later declined. Regeneron is collaborating with Sanofi on the development.

Regeneron Pharmaceuticals (REGN) reported positive Phase 2 trial results for trevogrumab, showing it preserves muscle mass during weight loss. The stock is trading at $729.20, 19.6% below its GF Value™ of $907.43, indicating modest undervaluation. The company has a GF Score™ of 88, reflecting strong fundamentals, but insiders have been net sellers.